Analysts Set Clementia Pharmaceuticals Inc (CMTA) Price Target at $26.60
Shares of Clementia Pharmaceuticals Inc (NASDAQ:CMTA) have been assigned an average recommendation of “Buy” from the seven analysts that are covering the company, MarketBeat Ratings reports. One equities research analyst has rated the stock with a sell rating, one has given a hold rating and five have given a buy rating to the company. The average twelve-month price target among analysts that have covered the stock in the last year is $26.60.
Several analysts have recently issued reports on the company. B. Riley assumed coverage on Clementia Pharmaceuticals in a report on Wednesday, March 28th. They set a “buy” rating and a $25.00 price objective on the stock. Zacks Investment Research cut Clementia Pharmaceuticals from a “hold” rating to a “sell” rating in a report on Monday, May 14th. Finally, ValuEngine raised Clementia Pharmaceuticals from a “sell” rating to a “hold” rating in a report on Wednesday, May 2nd.
NASDAQ CMTA traded down $0.09 during trading hours on Monday, reaching $14.16. The company’s stock had a trading volume of 401 shares, compared to its average volume of 67,591. Clementia Pharmaceuticals has a 1 year low of $11.72 and a 1 year high of $20.15. The stock has a market cap of $438.03 million and a PE ratio of -1.79.
Institutional investors and hedge funds have recently modified their holdings of the company. A.R.T. Advisors LLC purchased a new stake in shares of Clementia Pharmaceuticals during the 1st quarter worth approximately $232,000. J. Goldman & Co LP purchased a new stake in shares of Clementia Pharmaceuticals during the 4th quarter worth approximately $488,000. Birchview Capital LP raised its holdings in shares of Clementia Pharmaceuticals by 72.7% during the 1st quarter. Birchview Capital LP now owns 38,000 shares of the company’s stock worth $576,000 after acquiring an additional 16,000 shares in the last quarter. Alps Advisors Inc. raised its holdings in shares of Clementia Pharmaceuticals by 21.0% during the 1st quarter. Alps Advisors Inc. now owns 40,943 shares of the company’s stock worth $620,000 after acquiring an additional 7,116 shares in the last quarter. Finally, Victory Capital Management Inc. increased its position in shares of Clementia Pharmaceuticals by 12.7% during the 4th quarter. Victory Capital Management Inc. now owns 34,710 shares of the company’s stock valued at $659,000 after purchasing an additional 3,920 shares during the last quarter. 71.24% of the stock is currently owned by institutional investors and hedge funds.
About Clementia Pharmaceuticals
Clementia Pharmaceuticals Inc, a clinical stage biopharmaceutical company, develops treatments for patients suffering from bone disorders and other diseases. Its lead product candidate is palovarotene, an oral small molecule for the treatment of fibrodysplasia ossificans progressive, multiple osteochondromas, dry eye disease, and other diseases is in the Phase 3 MOVE Trial.
Receive News & Ratings for Clementia Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Clementia Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.